Sai Life Sciences Q1FY26 Revenue Rises 77 Per Cent YoY

08 Aug 2025 CW Team

Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.

Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.

Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.

Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.

To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.

Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”

CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”

Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Your next big infra connection is waiting at RAHSTA 2025 – Asia’s Biggest Roads & Highways Expo, Jio World Convention Centre, Mumbai. Don’t miss out!

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO), reported strong financial results for the first quarter of fiscal year 2026, led by significant growth in its CDMO segment.Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Infrastructure Transport

01 Sep 2025

Indian Railways Marks New Milestone with 4.5 km Long ‘Rudrastra’ Trial

Indian Railways has successfully conducted the trial run of Asia’s longest freight train, named ‘Rudrastra’, achieving a new milestone in cargo transportation, as per news reports. The 4.5 km-long train began its trial from Ganjkhwaja railway station in Chandauli, Uttar Pradesh, and travelled to Garhwa in Jharkhand. Covering a distance of 209 km in 5 hours and 10 minutes, it maintained an average speed of 40.5 km per hour. The train was formed by combining three long-haul racks, with ..

Infrastructure Energy

01 Sep 2025

UltraTech Launches India’s First On-Site Hybrid RTC Renewable Energy Project

UltraTech Cement has operationalised a 7.5 MW round-the-clock (RTC) hybrid renewable energy project at its Sewagram Cement Works in Gujarat. The first-of-its-kind solution combines bifacial solar modules with trackers, wind energy and battery storage, co-located on-site, to ensure uninterrupted power for cement manufacturing without grid reliance. The project was executed in collaboration with clean energy solutions provider Gentari. Installed as a behind-the-meter system, it is the country..

Infrastructure Transport

09 Sep 2025

Patna Metro Trials Successful, Red Line Priority Corridor to Launch This Month

Patna is set to roll out its first metro rail service later this month, with successful trial runs conducted on the Red Line priority corridor, the Patna Metro Rail Corporation announced.On 7 September, a metro train completed a test run between the Patna depot and Bhootnath station. Officials said the trials involved rigorous checks of rolling stock fitness, overhead electrification (OHE), and track alignment and stability to ensure operational safety and performance.The corridor from the New Pataliputra Bus Terminal to Bhoothnath has been designated as the priority stretch and will be the fi..